MYL) today announced that its Indian subsidiary,
Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of SovaldiĀ® (sofosbuvir 400mg tablets) and HarvoniĀ®(ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. As Gilead's exclusive branded medicine distribution partner, Mylan expects to begin distribution of Sovaldi in India in Q2 2015.